Chronic Hand Eczema Relief Data Reported
New findings for delgocitinib cream show improvements in skin clearance and quality of life for adults and adolescents.
Updated on Oct. 1, 2026 in Allergies
Live Poll
Should pharmaceutical companies prioritize patient-reported quality of life metrics when evaluating the success of new treatments?
Data presented at the EADV Congress indicates that delgocitinib cream may improve symptoms of chronic hand eczema in both adults and adolescents. These findings reflect improvements in skin appearance and reduced quality-of-life impacts for patients managing the condition.
Why it matters
Chronic hand eczema often carries significant functional and psychological burdens due to persistent pain and itch, which can interfere with daily activities. Research into novel treatment options is essential for managing these challenges and improving long-term outcomes for affected populations.
In the observational REACHED study conducted across 79 sites in Germany, 28.6% of adults achieved clear or almost clear skin status after 8 weeks of delgocitinib cream. The DELTA TEEN trial reported that 27% of adolescent participants experienced no quality-of-life impact at week 16.
The players
LEO Pharma
A Denmark-based pharmaceutical company focused on the development of dermatological treatments and therapies.
The details
Delgocitinib cream is being studied as a topical treatment for the inflammation associated with chronic hand eczema. The trials utilized tools such as the Hand Eczema Symptom Diary and the Children's Dermatology Life Quality Index to capture patient-reported changes in itch and pain intensity. These measures assess how the medication influences skin surface symptoms while concurrently evaluating the psychological and functional burden on the patient.
Timeline
Patient enrollment for the REACHED study began on June 6, 2025.
The 35th EADV Congress took place in Vienna from September 30 to October 3, 2026.
Health Landscape
The study sits within the broader evolution of dermatological care, which increasingly emphasizes both clinical clearance and patient-reported quality-of-life metrics. These findings reflect the growing pipeline of targeted topical therapies intended to address the 4.7% global prevalence of hand eczema.
If you are managing chronic hand eczema, consider tracking your symptoms to discuss potential treatment options with your physician. It is worth asking your doctor whether new clinical developments, such as topical trial findings, might be relevant to your specific care plan.
The takeaway
Chronic hand eczema significantly affects daily function, but emerging data suggests that topical treatments may provide relief for both adults and adolescents. Tracking the frequency and intensity of your symptoms can provide a valuable baseline when speaking with your dermatologist about new options.
Further reading
For more on current research and approaches to managing skin conditions, visit our Allergies section.
Live Poll
Should pharmaceutical companies prioritize patient-reported quality of life metrics when evaluating the success of new treatments?
